• FluTrackers.com Inc. does not provide medical advice. Information on this web site is collected from various internet resources, and the FluTrackers board of directors makes no warranty to the safety, efficacy, correctness or completeness of the information posted on this site by any author or poster. The information collated here is for instructional and/or discussion purposes only and is NOT intended to diagnose or treat any disease, illness, or other medical condition. Every individual reader or poster should seek advice from their personal physician/healthcare practitioner before considering or using any interventions that are discussed on this website. By continuing to access this website you agree to consult your personal physican before using any interventions posted on this website, and you agree to hold harmless FluTrackers.com Inc., the board of directors, the members, and all authors and posters for any effects from use of any medication, supplement, vitamin or other substance, device, intervention, etc. mentioned in posts on this website, or other internet venues referenced in posts on this website.
  • We are not asking for any donations. Do not donate to any entity who says they are raising funds for us.

J Med Virol . Community and Hospital-Based Laboratory Surveillance for Influenza, Respiratory Syncytial Virus, and SARS-CoV-2 During the 2023-2024 S

tetano

Editor, Senior Moderator
J Med Virol


. 2025 Sep;97(9):e70549.
doi: 10.1002/jmv.70549. Community and Hospital-Based Laboratory Surveillance for Influenza, Respiratory Syncytial Virus, and SARS-CoV-2 During the 2023-2024 Season, Lyon, France

Cécile Chauvel[SUP] 1 2 [/SUP], Jean-Sébastien Casalegno[SUP] 3 4 [/SUP], Benoit Visseaux[SUP] 5 [/SUP], Vincent Vieillefond[SUP] 6 [/SUP], Stéphanie Haim-Boukozba[SUP] 7 [/SUP], Vincent Enouf[SUP] 8 [/SUP], Emmanuel Chanard[SUP] 9 [/SUP], Margaux Fabre[SUP] 10 [/SUP], Marie-Anne Rameix-Welti[SUP] 8 11 [/SUP], Antoine Oblette[SUP] 3 4 [/SUP], Jean-Marc Giannoli[SUP] 12 13 [/SUP], Juliette Paireau[SUP] 14 15 [/SUP], Laurence Josset[SUP] 3 4 [/SUP], Bruno Lina[SUP] 3 4 [/SUP], Alexandre Gaymard[SUP] 3 4 [/SUP], Simon Cauchemez[SUP] 14 [/SUP], Florence Morfin[SUP] 3 4 [/SUP], Marta C Nunes[SUP] 1 2 [/SUP], Antonin Bal[SUP] 3 4 [/SUP]



Affiliations
Abstract

Influenza, respiratory syncytial virus (RSV) and SARS-CoV-2 are among the main respiratory viruses circulating in the population, with a significant burden on public health. While individuals at higher risk are more likely to develop severe symptoms leading to hospitalization, viral circulation in the community remains less extensively monitored. This study compared viral circulation between RELAB, a recently established community-based laboratory surveillance network (n = 22 843 tested patients) and hospital surveillance at the Hospices Civils de Lyon, France (n = 23 046 tested patients), for the season 2023-2024. For influenza and SARS-CoV-2, similar trends were observed in at-risk populations (children under 5 years and adults over 65 years) in both settings. Circulation of these two viruses was first detected in the community and insights from the young adult population (19-64 years) were only captured in the community network. Circulation of RSV was more intense in terms of number of cases and started in the pediatric population, and consequently was more represented in the hospital setting. In conclusion, this study highlighted the complementarity between community and hospital surveillance, as different populations and periods of viral circulation were observed.

Keywords: RSV; SARS‐CoV‐2; community; hospital; influenza; surveillance network.

 
Back
Top Bottom